Sunlenca® (lenacapavir) Receives FDA Approval as a First-in-Class, Twice-Yearly Treatment Option for People Living With Multi-Drug Resistant HIV

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Sunlenca^® (lenacapavir), in combination with other antiretroviral(s) (ARV), has been granted approval by the U.S. Read More